Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SAN DIEGO -- Businesswire -- AOP Orphan Pharmaceuticals GmbH (AOP Health), Vienna, Austria, announced the results of an analysis assessing the impact of an individually optimized dosing regimen of ropeginterferon alfa-2b on treatment response in patients with low-risk polycythaemia vera (PV)1 These new data show that some low-risk PV patients require and can tolerate high ropeginterferon alfa-2b doses, and that the optimal dose varies substantially between patients.
The first author of the abstract, Professor Heinz Gisslinger from the Medical University of Vienna/Austria, and his research team conducted the present analysis in the cohort of low-risk PV patients from the large trial PROUD-PV and its extension CONTINUATION-PV. The goal was to examine the impact of various baseline characteristics such as body mass index as well as individually optimized dose levels of ropeginterferon alfa-2b on complete hematologic response (CHR), the state when blood cell counts have returned to normal, at 12, 24, and 72 months.[1]
“The results of this analysis expand the depth of data and add the clinically relevant and important evidence which can support health care professionals in their treatment decisions”, Gisslinger concludes.
[1] Gisslinger H et al. Individualized dosing of ropeginterferon alfa-2b ensures optimal response in patients with low-risk polycythemia vera (PV). ASH 2023, Abstract #4563 (https://ash.confex.com/ash/2023/webprogram/Paper173499.html)
About Polycythaemia Vera Polycythaemia Vera (PV) is a rare cancer of the blood-building stem cells in the bone marrow resulting in a chronic increase of red blood cells, white blood cells and platelets. This condition increases the risk for circulatory disorders such as thrombosis and embolism, its symptoms lead to a reduced quality of life and on the long run may progress to myelofibrosis or transform to leukemia. While the molecular mechanism underlying PV is still subject of intense research, current results point to blood-building stem cells in the bone marrow with a set of acquired mutations, the most important being a mutant form of JAK2 that make up the malignant clone.
Important PV treatment goals are to achieve healthy blood counts (hematocrit below 45%), improve quality of life and to slow or delay the progression of disease.
About AOP Health The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other - especially the patients and their families as well as also the healthcare professionals treating them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231207901630/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:AOP Orphan Pharmaceuticals AG
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 한화에어로스페이스, 선박용 수소연료전지 AIP 인증 획득 - 뉴스와이어
- HD현대사이트솔루션, 국내 최대 5톤급 수소지게차 첫 공급 - 뉴스와이어
- 핀크스 골프클럽, 여름밤 그린 위에서 즐기는 이색 바베큐 ‘그린사이드BBQ’ 오픈 - 뉴스와이어
- 신한카드, 사회초년생을 위한 첫 신용카드 ‘신한카드 처음’ 출시 - 뉴스와이어
- 국립심포니, 한국 작곡가 미국 진출 교두보 마련 - 뉴스와이어
- SK C&C, 기업별 클라우드에서 안전하고 빠르게 생성형 AI 연동 지원하는 ‘AI 랜딩존’ 선보여 - 뉴
- 지투파워, 113억 ESS ‘액침 냉각’ 정부 과제 수주 - 뉴스와이어
- 아르텔 필하모닉 오케스트라 ‘마이 레전더리 팝스’ 개최 - 뉴스와이어
- ‘제10회 국제 불교무용대전’ 개최… 한국·인도·일본·베트남 등 아시아 아우르는 화려한 불교
- 유병재 샌드박스네트워크 계약 종료, 작가·PD 위한 소속사 블랙페이퍼로 이적 - 뉴스와이어